S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
S&P 500   5,096.27 (+0.52%)
DOW   38,996.39 (+0.12%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)

4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis

$28.02
+0.13 (+0.47%)
(As of 02/29/2024 ET)
Today's Range
$27.85
$29.13
50-Day Range
$17.03
$33.21
52-Week Range
$9.44
$35.61
Volume
477,076 shs
Average Volume
1.36 million shs
Market Capitalization
$1.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.44

4D Molecular Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
40.8% Upside
$39.44 Price Target
Short Interest
Bearish
16.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.65mentions of 4D Molecular Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$14.99 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.54) to ($3.02) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.45 out of 5 stars

Medical Sector

764th out of 958 stocks

Biological Products, Except Diagnostic Industry

127th out of 160 stocks


FDMT stock logo

About 4D Molecular Therapeutics Stock (NASDAQ:FDMT)

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

FDMT Stock Price History

FDMT Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
4DMT Secures FDA RPDD For Aerosolized 4D-710
See More Headlines
Receive FDMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
2/29/2024
Next Earnings (Estimated)
3/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FDMT
Fax
N/A
Employees
144
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.44
High Stock Price Target
$81.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+41.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-107,490,000.00
Net Margins
-436.30%
Pretax Margin
-436.30%

Debt

Sales & Book Value

Annual Sales
$21.99 million
Book Value
$7.14 per share

Miscellaneous

Free Float
38,179,000
Market Cap
$1.19 billion
Optionable
Optionable
Beta
2.63
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. John F. Milligan Ph.D. (Age 63)
    Executive Chairman
    Comp: $150k
  • Dr. David H. Kirn M.D. (Age 62)
    Co-Founder, CEO & Director
    Comp: $920.97k
  • Dr. Fariborz Kamal Ph.D. (Age 61)
    President & COO
    Comp: $678.4k
  • Dr. Noriyuki Kasahara M.D. (Age 61)
    Ph.D., Chief Scientific Officer
    Comp: $13.6k
  • Ms. Theresa Janke (Age 49)
    Co-Founder & Chief of Staff
    Comp: $652.32k
  • Mr. Uneek Mehra (Age 52)
    Chief Financial & Business Officer
  • Dr. Scott P. Bizily J.D. (Age 51)
    Ph.D., Chief Legal Officer & Corporate Secretary
  • Dr. Robert Y. Kim M.B.A. (Age 63)
    M.D., Chief Medical Officer
  • Dr. An Song Ph.D.
    Chief Development Officer
  • Dr. Alan H. Cohen FAAAAI (Age 63)
    FAAP, FACAAI, FCCP, M.D., Senior VP & Therapeutic Area Head of Pulmonology














FDMT Stock Analysis - Frequently Asked Questions

Should I buy or sell 4D Molecular Therapeutics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 4D Molecular Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FDMT shares.
View FDMT analyst ratings
or view top-rated stocks.

What is 4D Molecular Therapeutics' stock price target for 2024?

9 Wall Street analysts have issued 1-year price objectives for 4D Molecular Therapeutics' stock. Their FDMT share price targets range from $13.00 to $81.00. On average, they expect the company's share price to reach $39.44 in the next year. This suggests a possible upside of 40.8% from the stock's current price.
View analysts price targets for FDMT
or view top-rated stocks among Wall Street analysts.

How have FDMT shares performed in 2024?

4D Molecular Therapeutics' stock was trading at $20.26 at the beginning of the year. Since then, FDMT shares have increased by 38.3% and is now trading at $28.02.
View the best growth stocks for 2024 here
.

Are investors shorting 4D Molecular Therapeutics?

4D Molecular Therapeutics saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 7,060,000 shares, an increase of 83.9% from the January 31st total of 3,840,000 shares. Based on an average trading volume of 994,000 shares, the days-to-cover ratio is presently 7.1 days.
View 4D Molecular Therapeutics' Short Interest
.

When is 4D Molecular Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our FDMT earnings forecast
.

How were 4D Molecular Therapeutics' earnings last quarter?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) released its earnings results on Wednesday, November, 10th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.81) by $0.01. The business had revenue of $1.37 million for the quarter. 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative trailing twelve-month return on equity of 34.73%.

What ETFs hold 4D Molecular Therapeutics' stock?

ETFs with the largest weight of 4D Molecular Therapeutics (NASDAQ:FDMT) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

When did 4D Molecular Therapeutics IPO?

(FDMT) raised $101 million in an initial public offering on Friday, December 11th 2020. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

Who are 4D Molecular Therapeutics' major shareholders?

4D Molecular Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.37%), Novo Holdings A S (3.51%), Goldman Sachs Group Inc. (1.91%), Dimensional Fund Advisors LP (1.63%), Point72 Asset Management L.P. (0.97%) and Northern Trust Corp (0.85%). Insiders that own company stock include David Kirn, David Schaffer, Global Investors Lp Viking, Jacob Chacko, Robert Young Kim and Scott Bizily.
View institutional ownership trends
.

How do I buy shares of 4D Molecular Therapeutics?

Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FDMT) was last updated on 2/29/2024 by MarketBeat.com Staff